HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

China Healthcare Weekly (Jan.28) - 7th National VBP, Taking History as a Mirror, Confidence Rebuilt

Pre-IPO HeMo Bioengineering - Insights on Industry, Business and Concerns

China Healthcare Weekly (Feb.4)- "14th Five-Year Plan" Of Pharmaceuticals, the Right Way to Innovate

The CXO/Biotech Plunge and the Afterwards Investment Logic (2022)

The Insecure Rebound in Healthcare Sector and the Future Direction of Stock Price (2022)

The Concerns and Outlook About the Recent Rally in Traditional Chinese Medicine (TCM) Sector

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Thematic (Sector/Industry)

Hong kong Healthcare equipment and services / Thematic (Sector/Industry)

<ul>
<li>Both generic drugs and innovative drugs are facing the problem of “shortened life cycle” in China, pushing pharmaceutical companies to optimize product mix and find some shortcut, such as license-in.</li>
<li>However, it has been more and more difficult to in-license cost-effective products, indicating that the afterwards commercialization could be hard to cover the license-in cost or make decent profits.. </li>
<li>A way out is to <strong>reshape the development path</strong> after license-in by relying on strong R&amp;D systems, so as to achieve truly valuable innovation and thus maximize the commercialization value. </li>
</ul>


Both generic drugs and innovative drugs are facing the problem of “shortened life cycle” in China, pushing pharmaceutical companies to optimize product mix and find some shortcut, such as license-in.
However, it has been more and more difficult to in-license cost-effective products, indicating that the afterwards commercialization could be hard to cover the license-in cost or make decent profits.. 
A way out is to reshape the development path after license-in by relying on strong R&amp;D systems, so as to achieve truly valuable innovation and thus maximize the commercialization value. 


A Second Thought on the License-In Mode - Dilemmas and Solutions